Risk of Incident Inflammatory Bowel Disease Among Patients With Psoriasis Treated With IL-17 Versus TNF Inhibitors: A Propensity-Matched TriNetX Study (ACG 2026) - Aug 29, 2026 - Abstract #P5622; Pres time: Oct 13, 2026; 10:30 AM - 04:00 PM; Location: Exhibit Halls A - D (Level 3); "Adults (â¥18 years) with psoriasis initiating an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab, or bimekizumab) were compared with those starting a TNF inhibitor (adalimumab, infliximab, golimumab, or certolizumab pegol) after diagnosis...Cohorts underwent 1:1 propensity score matching on age, sex, race, ethnicity, diabetes, obesity, celiac disease, tobacco use, psoriatic arthritis (a disease-severity marker), and NSAID, antimicrobial, glucocorticoid, and methotrexate use, yielding 20,547 patients per cohort... After excluding prior IBD, 20,368 IL-17 and 18,987 TNF inhibitor users remained. At 1 year, incident IBD occurred in 46 IL-17 versus 79 TNF users (0.2% vs 0.4%), with significantly lower risk for IL-17 (relative risk [RR] 0.54, 95% CI 0.38â0.78; hazard ratio [HR] 0.56, 95% CI 0.39â0.81; log-rank p=0.002). At 3 years, IBD occurred in 85 versus 161 patients (0.4% vs 0.8%; RR 0.49, 95% CI 0.38â0.64; HR 0.54, 95%..."
Clinical • Celiac Disease • Crohn's disease • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Nicotine Addiction • Obesity • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL17A
|
|
Toufic Dabit MD 1; Bsher Almaalouli MD 2; Yeshika Thapa MD 2; Farah Haneyah MD 1; Murad Haddad MD 2; Yaseen Perbtani DO 3; Tony Brar MD 3; Amro Muflih 4
|